Yes, I believe that the confusion might arise from the fact that both Liau and NWBO are involved with murcidencel. This does not mean that Liau is an employee of NWBO—she is not. Dr. Liau is an employee of UCLA.
Dr. Bosch of Northwest Biotherapeutics is one of the coauthors of the murcidencel paper that Dr. Liau will present at SNO, but UCLA is the institution that employs Dr. Liau.
The Regents of UCLA likely have received royalties from the Specials Program in the UK once it became at least partially a commercially operated program. Up until transfer to Sawston and being run by Advent the program was being run exclusively by a research hospital so likely no royalties. Dr. Linda Liau began reporting a connection to NWBO after Sawston treated their first commercially (non research hospital) treated patient under the Specials Program. Since Dr. Linda Liau is compensated by UCLA she would be required to report the connection to the royalty payments through the Regents no matter how minuscule those payments might be or how negligible any part of that was used as compensation to her out of the overall budget by which the Regents are guided. No need to thank me, just glad to help get us all on the same page. Go NWBO!!!; ). Best wishes.
Market Data 
Markets 
AI
